ASX RELEASE

RACE ONCOLOGY INVESTOR CONFERENCE CALL

10 March 2017: Specialty pharmaceutical company, Race Oncology Ltd (ASX: RAC) is pleased to advise that the Company will host a conference call for investors on **Thursday, 16 March 2017** at the times listed below.

Race CEO Peter Molloy and Chairman Dr Bill Garner will be on the call to answer shareholder questions. The conference call will include a brief introduction from the CEO on the Company and its progress, with the remainder of the session dedicated to shareholders' questions. Investors may wish to review the Company's updated Investor Presentation released 9 March 2017, as this will be referenced during the conference call.

Questions may be submitted ahead of the conference call via email to:
investors@raceoncology.com

Conference call details:

Date: Thursday, 16 March 2017

Time: 2:00pm Sydney time (AEDT) / 11:00am Perth time (AWST) – participants are requested to dial in 5 minutes prior to the start time

Conference ID: 8392 8573

Dial-in numbers:

Domestic participants can dial either of the numbers below to join the call.

Toll Free: 1800 123 296 or Toll: +61 2 8038 5221

International toll-free numbers are listed below. For countries not listed below, the Australian Toll number can be dialled.

Canada:	1855 5616 766	New Zealand:	0800 452 782
China:	4001 203 085 / 8008 702 411	Singapore:	800 616 2288
Hong Kong:	800 908 865	United Kingdom:	0808 234 0757
India:	1800 3010 6141	United States:	1855 293 1544
Japan:	0120 477 087		

For shareholders not able to listen in at the time of the conference call, an archived copy of the call will be available shortly after via http://www.openbriefing.com/OB/2474.aspx

About Race Oncology

Race Oncology Limited is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company's goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit **raceoncology.com** for more information.

For more information, contact:

Peter Molloy T: +61 (0) 3 9097 1656
Managing Director E: plmolloy@raceoncology.com

Investor Relations
F T I Consulting
T: +61 (0)8 9485 8888
E: Elodie.Castagna@fticonsulting.com / Steve.Suleski@fticonsulting.com